medulloblastoma: current treatment and future directions
DESCRIPTION
MEDULLOBLASTOMA: Current Treatment and Future Directions. James T Rutka, MD, PhD, FRCSC, FACS Division of Neurosurgery The Hospital for Sick Children The University of Toronto. The Past. Cushing and Pediatric Neurosurgery. Cushing and Pediatric Brain Tumours. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/1.jpg)
MEDULLOBLASTOMA: Current Treatment and Future
Directions
• James T Rutka, MD, PhD, FRCSC, FACS• Division of Neurosurgery
• The Hospital for Sick Children• The University of Toronto
![Page 2: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/2.jpg)
![Page 3: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/3.jpg)
The Past
![Page 4: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/4.jpg)
Cushing and Pediatric Neurosurgery
![Page 5: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/5.jpg)
Cushing and Pediatric Brain Tumours
Acta Pathologica, Microbiologica etImmunologica Scandinavica 7:1-86, 1930
Surgery, Gynecology and Obstetrics52: 129-204, 1931
![Page 6: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/6.jpg)
Clinical Presentation of the Child with a Medulloblastoma
• “A preadolescent child previously in good health begins to complain of headaches or of suboccipital discomfort and to have occasional attacks of vomiting without preliminary nausea, usually on first arising in the morning…The family doctor, who has previously suspected some gastro-intestinal disorder, may then have the eyegrounds examined and to the surprise of everyone a choked disk is found…”
![Page 7: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/7.jpg)
Clinical Presentation of the Child with a Medulloblastoma
• “If not recognized so soon…the clumsiness increases, vomiting grows more frequent, the child begins to lose weight, the muscles become wasted and atonic; there may be a slight facial palsy; the internal squint may become bilateral; finally…extensor rigidities occur, ere this child becomes bedridden. The whole story if uninterrupted by operation may cover a period from 8-9 months”
Acta Path Microbiol Immunol Scandinavica 7: 1-86, 1930
![Page 8: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/8.jpg)
MEDULLOBLASTOMA• Contributions of Cushing and
Bailey– Coined term “medulloblastoma” 1925– Described patient presentations– 61 operative cases by 1930– Aware of tendency to invade brainstem
and to disseminate along CSF pathways
Operative sketch ofMedulloblastoma fromCushing’s Collection
![Page 9: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/9.jpg)
MEDULLOBLASTOMA• HISTORICAL LANDMARKS
– 1925 – Described by Cushing and Bailey
– 1953 – Patterson and Farr describe efficacy of craniospinal irradiation
– 1991 – Packer et al. describe efficacy of pre-irradiation chemotherapy
KG McKenzieCanada’s first neurosurgeon
![Page 10: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/10.jpg)
Medulloblastoma - The Evolution of Pediatric Neuro-radiology
• Skull Xrays• Angiography• Ventriculography• Pneumo-
encephalography• Myelography• CT Scan• PET• MRI• MEG• DTI
![Page 11: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/11.jpg)
Early CT Imaging ofPediatric Brain Tumors
Air encephalography
Early CT scansCirca 1976
![Page 12: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/12.jpg)
MEDULLOBLASTOMA• HSC EXPERIENCE (1980 – 1990)
– NUMBER OF PATIENTS = 50– LOW RISK = 26; HIGH RISK = 24– LOW RISK 5 YR SURVIVAL = 70%– HIGH RISK 5 YR SURVIVAL = 40%
![Page 13: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/13.jpg)
MEDULLOBLASTOMA
• IMPROVING PATIENT SURVIVAL– 63 high risk children; cis-plat, VCR, CCNU– PFS @ 5 yrs = 85% for entire group– PFS @ 5 yrs = 67% for children with
metastases– PFS @ 5 yrs = 90% for children with local
disease– Packer et al, J Neurosurg 81: 690, 1994
![Page 14: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/14.jpg)
The Present
![Page 15: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/15.jpg)
MEDULLOBLASTOMA
• Most common malignant neoplasm of the CNS in children (15-20% of childhood brain tumors)
• Peak incidence between 3 and 8 years
• Slight male predominance
![Page 16: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/16.jpg)
MEDULLOBLASTOMA• BIOLOGICAL BEHAVIOUR
– 40% infiltrate the brainstem– 20-50% CSF dissemination along the
neuraxis– 10% systemic metastases (lung,
lymph node, bone)
Diffuse bone mets CSF spread Met along shunt tubing
The Harold J Hoffman Slide Collection
www.surg.med.utoronto.ca/neuro/slides.html
![Page 17: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/17.jpg)
MEDULLOBLASTOMARISK SEGREGATIONLow Risk High Risk
> 3 yrs < 3 yrsNo residual tumor > 1.5 cm2 residualNo distant metastases Metastases
All patients with medulloblastoma are high riskKintomo Takakura
![Page 18: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/18.jpg)
MEDULLOBLASTOMA
• IMAGING STUDIES– Hyperdense lesion
on CT before contrast
– Heterogeneous enhancement after contrast
Pre-contrast Post-contrast
![Page 19: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/19.jpg)
MEDULLOBLASTOMA
TUMOR LOCATIONMidline, vermianHemisphericCP angleBrainstem (rare)Supratentorial (PNET)
Pre-operative MRI Spine!!
![Page 20: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/20.jpg)
MEDULLOBLASTOMA: Spine MRI
Pre-operative spinal imaging is mandatory!
![Page 21: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/21.jpg)
MEDULLOBLASTOMA: Imaging
Diagnosis of leptomeningeal disease
![Page 22: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/22.jpg)
MedulloblastomaLessons learned
• TO SHUNT OR NOT TO SHUNT?– Do not shunt unless the child is
moribund from acute obstructive hydrocephalus
– Most children will be symptomatically controlled by steroids
![Page 23: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/23.jpg)
MEDULLOBLASTOMA
• OPERATIVE APPROACH– Midline, vermian
split– Lateral
hemispheric– Inferior
medullary velum - telovelar
– CP angle
![Page 24: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/24.jpg)
MEDULLOBLASTOMA
Removing tumor fromFloor of IVth
Inspecting anatomical Structures with tumorremoved
INTRA-OPERATIVE NUANCES
![Page 25: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/25.jpg)
Intra-operative video
![Page 26: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/26.jpg)
MEDULLOBLASTOMA
Surgery, XRTAnd Chemo
5 years
Surgery, XRT And Chemo
4 years
![Page 27: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/27.jpg)
With Medulloblastoma, the More Tumor You Remove, the Better!
![Page 28: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/28.jpg)
MEDULLOBLASTOMA
• POST-OPERATIVE COMPLICATIONS– Cerebellar, cranial nerve deficits– Hydrocephalus requiring shunt or ETV– Meningitis– Pseudomeningocele– Cerebellar Mutism
![Page 29: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/29.jpg)
![Page 30: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/30.jpg)
MedulloblastomaHow to avoid cerebellar
mutism?• Nobody knows!• Work quickly and efficiently with the
cavitron• Avoid self retaining retractor
systems.• Be careful with traction on or
dissection into the cerebellar peduncles
• Assess tractography post-op!Lancet Oncology June 2008
![Page 31: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/31.jpg)
MEDULLOBLASTOMAEffects of XRT on the CNS
• Neurocognitive• Moya moya• Endocrinopathy• Vasculopathy• Cavernous
malformation• Secondary
neoplasms
![Page 32: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/32.jpg)
NEJM 2005:352:978-986
![Page 33: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/33.jpg)
Chemotherapy for Medulloblastoma
Proven effective but….
Cycles of chemotherapyStem cell transplantInfectious complicationsToxic mortality
6 year old maleShort history GTRExcellent post-op course
![Page 34: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/34.jpg)
MEDULLOBLASTOMA
• CURRENT BEST TREATMENT• Maximum safe neurosurgical resection• Radiation therapy (reduced craniospinal
irradiation, avoid irradiating children < 3 yrs)
• Chemotherapy (active agents, autologous stem cell transplant, new agents)
5 year survival standard risk – 70%5 year survival high risk – 50%
![Page 35: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/35.jpg)
Future Treatment of Medulloblastoma
• Advanced Cytogenetics
• Differential Gene Expression
• SNP array platforms• Next generation
sequencing• Epigenetics• Stem Cells
![Page 36: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/36.jpg)
Advanced Cancer Cytogenetics
Chromosomes 7 & 17 rearrangementsGene amplification in 30% (2q)Loss of chromosome 10Three techniques led to identificationOf greatest number genetic alterations
![Page 37: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/37.jpg)
Examine a panel of differentially expressed genes in patient samples linked to clinical outcome and survival data.
Tissue Microarray Technology
![Page 38: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/38.jpg)
Tissue Array Prediction of Patient Outcome
![Page 39: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/39.jpg)
MEDULLOBLASTOMA ANDGERMLINE SUFU MUTATION
![Page 40: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/40.jpg)
The Globe and Mail June 20, 2002
Nature Genetics 31: 306-310, 2002
![Page 41: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/41.jpg)
Gene DiscoverycDNA microarray analysis
• Atlas 1200 gene cancer array
• Ability to find genes that are both up- and down-regulated compared to normal cerebellum
• Gene discovery strategy
![Page 42: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/42.jpg)
SamplesMedulloblastoma cell lines (DAOY, TE671, UW426, ONS76 ) and Human adult cerebellum
Gene Discovery Experiment Using:GeneChip Affymetrix Human Genome U133 Plus 2.0 ArrayComprehensive coverage of the human genomeMore than 47,000 transcripts studied
Hybridization Scanning Analysis
Flowchart of the procedure
The Future of Medulloblastoma
![Page 43: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/43.jpg)
Hierarchical Clustering of MAGE and GAGE by microarray
UW
426
DA
OY
ON
S76
TE
671
GAGE7GAGE7BGAGE3GAGE6GAGE4GAGE2MAGEA9GAGE1MAGEE1MAGEA10MAGEC1MAGEB3BAGEGAGEB1MGEA12MAGEA11MAGE6MAGEA3MAGEA8MAGEB4MAGEB2MAGEB1MAGEA1MAGE1
Cell lines
BAGE GAGE4GAGE1 GAGE2MAGEB4MAGEB3GAGE7BGAGE6MAGEB2GAGE2MAGEA8MAGEA9GAGE1MAGEC1MAGEB1GAGE3MAGE1GAGE7MAGEA1MAGEA11GAGEB1MAGE10MGEA12MAGEE1MAGEA3MAGE6
Medulloblastoma tumor specimens
HM
B1
HM
B19
HM
B24
HM
B35
HM
B8
![Page 44: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/44.jpg)
Advanced Genetic Platforms
for Medulloblastoma1. Single nucleotide polymorphism (SNP) array platforms (CNAs)
2. PCR-directed exon resequencing3. DNA methylation assays (epigenetics)4. DNA histone alterations (epigenetics)5. Next generation (“deep”) DNA
sequencing (454 Roche, Solexa Illumina, SOLiD Applied Bioscience)
![Page 45: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/45.jpg)
Resources Resolution Results
1-10 Mb
5-10 Kb
“small” dataset
“large” dataset
~20-30 samples
212 samples
Previous studies:
Current study:
=
![Page 46: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/46.jpg)
100K & 500K GeneChip Mapping Arrays
Amplifications: 191
Homozygous Deletions: 159
212 MBs
(201 primaries, 11 cell lines)
Known genes/pathways
- Myc family
- PDGF signaling
- OTX2
Novel genes/pathways
- chromatin: H3K9
Strategy for identification of novel genetic events in medulloblastoma…
![Page 47: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/47.jpg)
Whole genome copy numberprofiling of MB
![Page 48: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/48.jpg)
Animal Models More Reliably Predicting Clinical Response
• Ptch• Ptch + p53• XRCC4 knockout• Smo activation• Shh injection• Lig4 + p53• Parp + p53• Shh + Akt or IGF2 Sufu
Sufu + Costal2Gli2
![Page 49: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/49.jpg)
MURINE MRI
Medulloblastoma in PTCH+/- Mice
![Page 50: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/50.jpg)
Gene Silencing in Medulloblastoma
![Page 51: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/51.jpg)
--Chromatin remodelerHistones --Transcription
--Histone tails
MicroRNAsChromosome
DNA methylationEpigenetic MechanismsIn Medulloblastoma
Nature, 2008
![Page 52: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/52.jpg)
Role of epigenetic silencing in medulloblastoma
Cancer Res Dec 2008
![Page 53: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/53.jpg)
Mice Implanted with SPINT2 Expressing MB Cells Have Prolonged Survival
![Page 54: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/54.jpg)
What is SPINT2?A Novel Target for HGF/cMET inhibition
• Chr 19q13• 28.2 kDa• Serine protease
inhib• Dissection of
downstream signaling pathways
• HGF/cMET pathway inhibition (small molecule PHA-665752)
![Page 55: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/55.jpg)
STEM CELLS AND MEDULLOBLASTOMA
![Page 56: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/56.jpg)
Stem Cells andHuman Malignant Brain
Tumors
![Page 57: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/57.jpg)
CD15/ LeX /SSEA1Gal1-4(Fuc1-3)GlcNAc-
Sally TempleNeuron 35: 865, 2002Developmental Biology 291:300, 2006
Adult Brain Embryonic Brain
GFAP
A new stem cell marker!
![Page 58: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/58.jpg)
Targeting the Brain Tumor Stem CellImplications for Treatment
Reya et al, Nature 414: 105-111, 2001
![Page 59: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/59.jpg)
Medulloblastoma: Prediction 2019
• Imaging diagnosis of tumor• Stereotactic biopsy for molecular
profiling and subclassification• Chemotherapy alone (conventional
and novel pharmacotherapeutics)• Aggressive surgical therapy and
radiation therapy will be relegated to the past
![Page 60: MEDULLOBLASTOMA: Current Treatment and Future Directions](https://reader030.vdocuments.net/reader030/viewer/2022020716/56812b44550346895d8f5be8/html5/thumbnails/60.jpg)
Thank you!